Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib plus cyclosporin in refractory immune thrombocytopenia (Phase II, single-arm)
ChiCTR2400081061Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Feb 2024
- Modality
- Small Molecules, Peptides, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib and cyclosporine in immune thrombocytopenia (ITP), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Response rate. Started Feb 2024; status: recruiting.
02
Drugs
zanubrutinibcyclosporine
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on ChiCTR2400081061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081061.